Literature DB >> 20130054

Contribution of vaccine-induced immunity toward either the HA or the NA component of influenza viruses limits secondary bacterial complications.

Victor C Huber1, Ville Peltola, Amy R Iverson, Jonathan A McCullers.   

Abstract

Secondary bacterial infections contribute to morbidity and mortality from influenza. Vaccine effectiveness is typically assessed using prevention of influenza, not secondary infections, as an endpoint. We vaccinated mice with formalin-inactivated influenza virus vaccine preparations containing disparate HA and NA proteins and demonstrated an ability to induce the appropriate anti-HA and anti-NA immune profiles. Protection from both primary viral and secondary bacterial infection was demonstrated with vaccine-induced immunity directed toward either the HA or the NA. This finding suggests that immunity toward the NA component of the virion is desirable and should be considered in generation of influenza vaccines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20130054      PMCID: PMC2849504          DOI: 10.1128/JVI.02621-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Unidirectional RNA polymerase I-polymerase II transcription system for the generation of influenza A virus from eight plasmids.

Authors:  Erich Hoffmann; Robert G Webster
Journal:  J Gen Virol       Date:  2000-12       Impact factor: 3.891

2.  Influenza and the interaction of viruses and bacteria in respiratory infections.

Authors:  C G Loosli
Journal:  Medicine (Baltimore)       Date:  1973-09       Impact factor: 1.889

3.  Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae.

Authors:  Jonathan A McCullers; Kimberly C Bartmess
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

4.  The impact of influenza epidemics on hospitalizations.

Authors:  L Simonsen; K Fukuda; L B Schonberger; N J Cox
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

5.  Influenza and the winter increase in mortality in the United States, 1959-1999.

Authors:  Thomas A Reichert; Lone Simonsen; Ashutosh Sharma; Scott A Pardo; David S Fedson; Mark A Miller
Journal:  Am J Epidemiol       Date:  2004-09-01       Impact factor: 4.897

Review 6.  Respiratory viruses predisposing to bacterial infections: role of neuraminidase.

Authors:  Ville T Peltola; Jonathan A McCullers
Journal:  Pediatr Infect Dis J       Date:  2004-01       Impact factor: 2.129

7.  Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor.

Authors:  Jonathan A McCullers; Jerold E Rehg
Journal:  J Infect Dis       Date:  2002-07-10       Impact factor: 5.226

8.  Antiviral activity of antiserum specific for an influenza virus neuraminidase.

Authors:  E D Kilbourne; W G Laver; J L Schulman; R G Webster
Journal:  J Virol       Date:  1968-04       Impact factor: 5.103

9.  Protection of mice with recombinant influenza virus neuraminidase.

Authors:  Edwin D Kilbourne; Barbara A Pokorny; Bert Johansson; Ian Brett; Youli Milev; James T Matthews
Journal:  J Infect Dis       Date:  2004-01-13       Impact factor: 5.226

10.  Mapping the antigenic and genetic evolution of influenza virus.

Authors:  Derek J Smith; Alan S Lapedes; Jan C de Jong; Theo M Bestebroer; Guus F Rimmelzwaan; Albert D M E Osterhaus; Ron A M Fouchier
Journal:  Science       Date:  2004-06-24       Impact factor: 47.728

View more
  28 in total

Review 1.  Secondary bacterial infections in influenza virus infection pathogenesis.

Authors:  Amber M Smith; Jonathan A McCullers
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

Review 2.  The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza.

Authors:  Amber M Smith; Victor C Huber
Journal:  Viral Immunol       Date:  2017-11-17       Impact factor: 2.257

Review 3.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

4.  Inactivated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super-infections.

Authors:  Michael S Chaussee; Heather R Sandbulte; Margaret J Schuneman; Frank P Depaula; Leslie A Addengast; Evelyn H Schlenker; Victor C Huber
Journal:  Vaccine       Date:  2011-04-08       Impact factor: 3.641

Review 5.  Preventing and treating secondary bacterial infections with antiviral agents.

Authors:  Jonathan A McCullers
Journal:  Antivir Ther       Date:  2011

6.  Live attenuated influenza vaccine, but not pneumococcal conjugate vaccine, protects against increased density and duration of pneumococcal carriage after influenza infection in pneumococcal colonized mice.

Authors:  Michael J Mina; Keith P Klugman; Jonathan A McCullers
Journal:  J Infect Dis       Date:  2013-07-11       Impact factor: 5.226

7.  Lethal coinfection of influenza virus and Streptococcus pneumoniae lowers antibody response to influenza virus in lung and reduces numbers of germinal center B cells, T follicular helper cells, and plasma cells in mediastinal lymph Node.

Authors:  Yuet Wu; Wenwei Tu; Kwok-Tai Lam; Kin-Hung Chow; Pak-Leung Ho; Yi Guan; Joseph S Malik Peiris; Yu-Lung Lau
Journal:  J Virol       Date:  2014-11-26       Impact factor: 5.103

8.  Limited Efficacy of Antibacterial Vaccination Against Secondary Serotype 3 Pneumococcal Pneumonia Following Influenza Infection.

Authors:  Dennis W Metzger; Yoichi Furuya; Sharon L Salmon; Sean Roberts; Keer Sun
Journal:  J Infect Dis       Date:  2015-02-03       Impact factor: 5.226

Review 9.  Immune dysfunction and bacterial coinfections following influenza.

Authors:  Dennis W Metzger; Keer Sun
Journal:  J Immunol       Date:  2013-09-01       Impact factor: 5.422

10.  A bivalent vaccine based on a replication-incompetent influenza virus protects against Streptococcus pneumoniae and influenza virus infection.

Authors:  Hiroaki Katsura; Zhenyu Piao; Kiyoko Iwatsuki-Horimoto; Yukihiro Akeda; Shinji Watanabe; Taisuke Horimoto; Kazunori Oishi; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.